Endocrinology and Diabetes —
Training activity: 5

Details

Perform and interpret the analyses to laboratory standard operating procedures on patients with:

• Hypo- and hyperparathyroidism
• Hypo- and hypervitaminosis D

Type

Entrustable training activity (ETA)

Evidence requirements

Evidence the activity has been undertaken by the trainee repeatedly, consistently, and effectively over time, in a range of situations. This may include occasions where the trainee has not successfully achieved the outcome of the activity themselves. For example, because it was not appropriate to undertake the task in the circumstances or the trainees recognised their own limitations and sought help or advice to ensure the activity reached an appropriate conclusion. ​

Reflection at multiple timepoints on the trainee learning journey for this activity.

Reflective practice guidance

The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.

Before action

What does success look like?

• Identify what is expected of you in relation to effectively performing and interpreting analyses related to calcium and bone metabolism disorders (PTH, vitamin D, calcium/phosphate) according to laboratory SOPs.
• Consider how the learning outcomes apply, specifically in relation to performing clinical and laboratory investigation, analysis and management of endocrine disorders and diabetes mellitus.
• Discuss with your training officer to gain clarity of what is expected of you in relation to key considerations for PTH and vitamin D analyses (e.g., sample type for ionised calcium, stability requirements, assay variability), and how to assess these results within the context of renal function.

What is your prior experience of this activity?

• Think about what you already know about performing and interpreting analyses for PTH, corrected and ionised calcium, phosphate, and vitamin D metabolites.
• Consider possible challenges you might face during the activity, such as interpreting complex calcium profiles (e.g., differentiating primary from tertiary hyperparathyroidism), understanding pseudohypoparathyroidism, or differentiating between vitamin D metabolite assays.
• Recognise the scope of your own practice for this activity i.e. know when you will need to seek advice or help, and from whom. You will need to seek advice from your Training Officer when required, for example if presented with a patient profile showing hypercalcaemia and inappropriately normal PTH, suggesting primary hyperparathyroidism or malignancy-associated hypercalcaemia.
• Acknowledge how you feel about embarking on performing and interpreting these specific analyses.

What do you anticipate you will learn from the experience?

• Consider the specific skills you want to develop, such as managing the stability requirements of PTH samples and accurately calculating corrected calcium values or differentiating types of hypovitaminosis D.
• Identify the specific insights you hope to gain into the test interpretation in the context of parathyroid and vitamin D disorders, or understanding the importance of biological variation when interpreting these analytes.

What additional considerations do you need to make?

• Consult actions identified following previous experiences of calcium/bone metabolism analyses where sample integrity or interpretation required critical review.
• Identify important information you need to consider before embarking on the activity, such as understanding the dynamic relationship between PTH, calcium, phosphate, and vitamin D; reviewing clinical guidelines for vitamin D deficiency treatment.

In action

Is anything unexpected occurring?

• Are you noticing anything surprising or different from what you anticipate whilst performing the analysis or interpreting results for calcium homeostasis?
• Are you encountering situations such as:
  • Discordant calcium and PTH levels that suggest a complex secondary cause or pseudohypoparathyroidism?
  • Analytical issues affecting the accuracy of Vitamin D metabolite measurement?
  • Difficulties interpreting results in the context of severe renal disease or complex co-morbidities?

How are you reacting to the unexpected development?

• How is this impacting your actions? For example, are you responding to the situation appropriately? Are you adapting or changing your approach to verify the result or troubleshoot the assay?
• Consider the steps you are taking in the moment, such as seeking guidance on suspected assay interference affecting PTH or Vitamin D results
• How are you feeling in that moment? For instance, are you finding it difficult to resolve discordant results? Is it affecting your confidence in assessing the biological activity of specific Vitamin D metabolites?

What is the conclusion or outcome?

• Identify how you are working within your scope of practice. For example, are you successfully correlating calcium and PTH results to confirm primary hyperparathyroidism? Or are you needing support because assay interference is suspected and requires specific methodological investigation?
• What are you learning as a result of the unexpected development? For example, are you mastering the technique for correlating calcium, phosphate, and PTH levels? Or gaining insight into the nuances of interpreting these analytes in the presence of severe renal disease?

On action

What happened?

• Begin by summarising the key steps you took when performing and interpreting the analyses for PTH and Vitamin D.
• Consider specific events, actions, or interactions which felt important, such as observing the stability and handling requirements for PTH samples or noting the necessity of calculating corrected calcium values during interpretation.
• Include any ‘reflect-in-action’ moments where you had to adapt to the situation as it unfolded, for instance, immediately investigating potential assay interference when PTH and calcium levels were unexpectedly discordant (e.g., hypercalcaemia with suppressed PTH).
• How did you feel during this experience, e.g., did you feel focused on understanding the calcium-PTH-vitamin D axis or stressed by the need to manage sample integrity for a labile analyte like PTH?

How has this experience contributed to your developing practice?

• Identify what learning you can take from this experience regarding PTH and vitamin D analysis and interpretation. What strengths did you demonstrate, e.g., accurate application of knowledge regarding the analytical methods for vitamin D metabolites?
• What skills and/or knowledge gaps were evident, e.g., unfamiliarity with interpreting complex profiles in tertiary hyperparathyroidism associated with severe renal disease?
• Compare this experience against previous engagement with similar activities – were any previously identified actions for development achieved? Has your practice improved in identifying potential analytical interferences in Vitamin D assays?
• Identify any challenges you experienced, such as needing to seek advice or clarification on scope of practice regarding the interpretation of a profile suggestive of pseudohypoparathyroidism, and how you reacted to this.

What will you take from the experience moving forward?

• Identify the actions or ‘next steps’ you will now take to support the assimilation of what you have learnt, including from any feedback you have received, with regards to ensuring accurate performance and interpretation of calcium-regulating hormones.
• What will you do differently next time you approach interpreting PTH results, for instance, by rigorously confirming the sample handling history to ensure PTH stability was maintained?
• Do you need to practise any aspect of the activity further, such as studying guidelines for monitoring vitamin D deficiency treatment or key learning outcomes related to understanding the differences between corrected and ionised calcium measurements?

Beyond action

Have you revisited the experiences?

• How have your subsequent experiences of managing calcium and bone metabolism assays and interpretation since completing this specific training activity led you to revisit your initial approach or decisions during that activity? For example, how an instance where a subsequent patient required differentiation between primary and tertiary hyperparathyroidism (often involving chronic kidney disease) forced you to re-evaluate the sufficiency of simple calcium/PTH correlation you applied during your first attempt at interpreting a routine hypercalcaemia profile?
• Considering what you understand about the interplay between PTH, calcium, phosphate, and vitamin D, and the influence of renal function and sample stability now, were the actions or considerations you identified after your initial reflection on this training activity sufficient? How have you since implemented or adapted improvements in your calcium homeostasis interpretation strategy based on further learning and experiences? For example, how you proactively reviewed and integrated specific departmental protocols on PTH sample handling to ensure stability, demonstrating you have adapted improvements based on further learning?
• Has discussing discordant calcium/PTH findings or the management of complex vitamin D assay results with colleagues, peers, or supervisors changed how you now view your initial experience in this training activity? For example, how professional storytelling with a senior colleague about a case where severe hypovitaminosis D was initially overlooked due to assay limitations refined your understanding of the critical nature of analytical awareness?

How have these experiences impacted upon current practice?

• How has the learning from this initial training activity, in combination with subsequent calcium and bone metabolism analysis experiences, contributed to your overall confidence and competence in effectively performing analysis and interpretation, particularly in preparing for assessments like Case-based Discussions (CBDs) or Observed Clinical Events (OCEs)? For example, how your accumulated ability in managing PTH sample integrity and interpreting the interplay between calcium, PTH, and vitamin D now enables you to confidently discuss complex hypercalcaemia investigations during a CBD assessment.
• How has reflecting back on this specific training activity, combined with everything you’ve learned since, shaped your current approach to calcium homeostasis analysis? How does this evolved understanding help you identify when something is beyond your scope of practice or requires escalation? For example, how your evolved approach means you now routinely check renal function and medication history when interpreting calcium homeostasis, and seek advice immediately when PTH/Calcium results are highly discordant or suggest complex tertiary disease, recognising this requires senior clinical consultation.
• Looking holistically at your training journey, how has this initial calcium and bone metabolism experience, revisited with your current perspective, contributed to your development in meeting the learning outcomes related to performing clinical and laboratory investigation, analysis and management of endocrine disorders and diabetes mellitus? For example, how this foundational experience has supported your development in understanding the factors affecting calcium and vitamin D status (e.g., renal function, medications).

Relevant learning outcomes

#	Outcome
# 1	Outcome Perform clinical and laboratory investigation, analysis and management of endocrine disorders.
# 2	Outcome Perform clinical and laboratory investigation, analysis and management of diabetes mellitus.